Skip Nav Destination
Issues
1 July 2012
-
Cover Image
Cover Image
The links between obesity (highly prevalent in many parts of the world) and claudin-low or basal-like breast cancers are unclear. Given the poor prognosis of these intrinsic breast cancer subtypes, the identification of mechanistic targets and strategies to prevent or control them is critical. The cover features an immunofluorescence photomicrograph (X60 magnification) of E-Wnt basal-like mammary tumors derived from MMTV-Wnt-1 transgenic mice. The epithelial morphology of these tumors is reflected by high expression of the common epithelial marker E-cadherin (green; nuclei are blue). E-cadherin expression is lost in M-Wnt claudin-low mammary tumors, which have a mesenchymal morphology and very poor prognosis. Diet-induced obesity significantly decreased E-cadherin expression and increased mesenchymal marker expression in E-Wnt cells, whereas calorie restriction increased E-cadherin expression and suppressed growth in both E-Wnt and M-Wnt tumors. Therefore, components of the epithelial-to-mesenchymal transition pathway represent possible targets for breaking the obesitybreast cancer link, particularly for the poor prognosis, often therapy-resistant subtypes basal-like and claudin-low breast cancers. See article by Dunlap et al. (beginning on page 930) for more information. - PDF Icon PDF LinkTable of Contents
ISSN 1940-6207
EISSN 1940-6215
Issue Sections
Reviews
Research Articles
Assessing Individual Breast Cancer Risk within the U.K. National Health Service Breast Screening Program: A New Paradigm for Cancer Prevention
D. Gareth R. Evans; Jane Warwick; Susan M. Astley; Paula Stavrinos; Sarah Sahin; Sarah Ingham; Helen McBurney; Barbara Eckersley; Michelle Harvie; Mary Wilson; Ursula Beetles; Ruth Warren; Alan Hufton; Jamie C. Sergeant; William G. Newman; Iain Buchan; Jack Cuzick; Anthony Howell
Letters to the Editor
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.